The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F05%3A00031906" target="_blank" >RIV/00216224:14110/05:00031906 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up

Popis výsledku v původním jazyce

The presented study aimed to assess whether the latter effect of pergolide in advanced Parkinson's disease remains stable also in the longer time period. Fourteen male patients suffering from Parkinson's disease, each of whom had been treated with L-DOPA, and in whom additional treatment with peroral dopaminergic agonist (DA) was needed, were followed for a six-months and twelve-months period. Pergolide mesylate (Permax (R)) was given to each patient, and titrated to a total daily dose of 3 mg. All of the patients were taking L-DOPA. There were statistically significant differences between the values of UPDRS III motor subscale, UPDRS IV (complications of therapy) subscale and all subscales of IIEF when months 0 and 1 were compared with the results obtained at months 3, 6 and 12. Pergolide mesylate, when added to L-DOPA, significantly improved sexual functions in younger male patients who were still interested in sexual activities in all aspects.

Název v anglickém jazyce

The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up

Popis výsledku anglicky

The presented study aimed to assess whether the latter effect of pergolide in advanced Parkinson's disease remains stable also in the longer time period. Fourteen male patients suffering from Parkinson's disease, each of whom had been treated with L-DOPA, and in whom additional treatment with peroral dopaminergic agonist (DA) was needed, were followed for a six-months and twelve-months period. Pergolide mesylate (Permax (R)) was given to each patient, and titrated to a total daily dose of 3 mg. All of the patients were taking L-DOPA. There were statistically significant differences between the values of UPDRS III motor subscale, UPDRS IV (complications of therapy) subscale and all subscales of IIEF when months 0 and 1 were compared with the results obtained at months 3, 6 and 12. Pergolide mesylate, when added to L-DOPA, significantly improved sexual functions in younger male patients who were still interested in sexual activities in all aspects.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2005

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Česká a slovenská neurologie a neurochirurgie

ISSN

1210-7859

e-ISSN

—

Svazek periodika

68

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

—

Kód UT WoS článku

000233791000006

EID výsledku v databázi Scopus

—